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S U M M A R Y
Background: Melioidosis is endemic in Malaysia, the southwest of Thailand, and northern Australia. The
incidence in Thailand is 4.4/1 000 000 inhabitants, where it causes 19% of community-acquired
pneumonia (CAP) and 20% of bacteremic pneumonia, and the mortality is 50%. Sporadic cases have been
described in Central and South America. The objective of this study was to describe the clinical and
epidemiological features and ecological characteristics of melioidosis in Antioquia, Colombia.
Methods: This is a case series description.
Results: Seven cases were identiﬁed. Burkholderia pseudomallei was isolated from peripheral blood,
pleural ﬂuid, and urine and was identiﬁed by the automated system VITEK 2 (bioMe´rieux) and API 20NE
biochemical kit. Five of the cases had a bacteremic form with shock and pulmonary compromise and two
of these patients died. The non-bacteremic melioidosis cases had genitourinary, abdominal, and
osteoarticular compromise. All patients had comorbidities and lived in rural hot and humid areas in the
west central region of Colombia (Antioquia). Diabetes mellitus, renal insufﬁciency, and other chronic
diseases are important risk factors for the development of severe forms.
Conclusions: The cases presented here are similar to those occurring in endemic areas regarding
comorbidity, risk factors, clinical presentation, and environmental conditions. It is necessary to establish
whether melioidosis is an endemic and under-diagnosed disease or an emerging disease in Colombia.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Melioidosis is a disease caused by Burkholderia pseudomallei, an
intracellular facultative Gram-negative saprophytic bacterium,1
distributed widely in the environment.2 Melioidosis is endemic in
Malaysia, southwest Thailand, northern Australia,1,3–7 Singapore,
Vietnam, Cambodia, and Laos.7,8 Australia and northeast Thailand
represent hot spots, with annual incidence rates of up to 50 cases§ Dr Montu´far is a specialist in internal medicine, pulmonology, epidemiology
and infectious diseases. He is now coordinator of the stewardship program at Pablo
Tobo´n Uribe Hospital, chief of the pulmonology unit at Leon XIII Clinic of Antioquia
University, and coordinator of the community-acquired pneumonia guidelines in
Colombia, published in Infectio in 2013.
* Corresponding author. Tel.: +57 4 3385563.
E-mail address: frmontufar@yahoo.com (F.E. Montu´far).
http://dx.doi.org/10.1016/j.ijid.2015.05.023
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).per 100 000 people.9–11 The incidence in Thailand is 4.4/
1 000 000 inhabitants, where it causes 19% of community-acquired
pneumonia (CAP) and 20% of bacteremic pneumonia, and the
mortality is 50%.3,4,11 Melioidosis is the third most common cause
of death from infectious disease in northeast Thailand, exceeded
only by HIV infection and tuberculosis.10,11 In northern Australia, it
is the most common cause of bacteremic CAP.4,5
In Central and South America, sporadic cases have been
described in Colombia, Panama, Ecuador, and Brazil.12–18 In
Colombia, there have been only two published cases of non-
bacteremic melioidosis.13,14
In endemic areas, the peak incidence is between 40 and
60 years19 and epidemics are associated with the winter or rainy
season. B. pseudomallei is usually found in shallow waters and in
damp soil between 25 and 45 cm deep.5 It has been proposed that
the bacteria surface when humidity is high.3–5,7–11ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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inoculation, or ingestion.1,3,5,7,8,15 Pulmonary involvement is very
important, and hematogenous spread leads to the involvement of
other organs.1,3–6,16 The inhalation of contaminated aerosols is
important in endemic areas, and it is considered a risk factor for
fatal pulmonary compromise. Less common cases occur by
inhalation/ingestion of contaminated water and following al-
most-drowning episodes.
The incubation period is related to the route of infection, the
inoculum size, microorganism virulence, and host factors. In
inhalation and almost-drowning cases the infection appears in less
than 24 h, and in percutaneous infection cases the incubation
period varies from 1 to 21 days, with an average of 9 days.4–6,16,20
The infection can be asymptomatic or present as an acute and
severe disease, especially in bacteremic forms with pulmonary
involvement in patients with comorbidities such as diabetes
mellitus, renal failure, alcoholism, structural pulmonary disease,
thalassemia, cancer, immunosuppression, and granulomatous
disease.1,3–6,8,15,11,21,22 Melioidosis may present relapses after
successful treatment and a sub-clinical infection period, of variable
length.
A group of Australian researchers5 has classiﬁed the infection
into bacteremic forms (with the absence or presence of shock) and
non-bacteremic forms. Each form may appear with pulmonary,
genitourinary, neurological, nodal, soft tissue, and osteoarticular
manifestations.1,4–7,12,20 The group of Howe et al. has classiﬁed the
infection into acute (sudden, with septic shock and suppurative
localized pneumonia), sub-acute, chronic, and sub-clinical forms.16
The diagnosis requires a high clinical and epidemiological
suspicion, combined with a good microbiological identiﬁcation
system such as microscopy and cultures complemented by
biochemical tests or latex agglutination. Serology is neither
speciﬁc nor sensitive, and at present molecular diagnostics are
mainly the domain of reference laboratories.15,23–28 Imaging is also
valuable to support the diagnosis.29,30
The treatment of melioidosis consists of an initial phase of
14 days of ceftazidime or carbapenems, followed by oral
eradication therapy, usually with trimethoprim–sulfamethoxazole
with or without tetracyclines for 3 to 6 months.24–31
A series of cases occurring in Antioquia, Colombia, which has
geographic regions and weather similar to those of endemic areas,
is presented below.
2. Case series
Seven cases were identiﬁed in three high-complexity hospitals
and reference centers in Medellı´n, Antioquia, Colombia: Pablo
Tobo´n Uribe Hospital (HPTU), Leon XIII Clinic of Antioquia
University, and San Vicente de Paul Hospital (HUSVP); these cases
occurred between January 1998 and December 2013. Clinical–
epidemiological characteristics are shown in Table 1, laboratory
ﬁndings are given in Table 2, and radiographic and computed
tomography (CT) manifestations are shown in Figure 1. The
ecological characteristics and geographic location of the cases are
shown in Figure 2 and Table 3.
B. pseudomallei was isolated from peripheral blood, pleural
ﬂuid, and urine. Samples were processed in the automated system
VITEK 2 (bioMe´rieux) and with the commercial API 20NE or 20E
biochemical kit with a simple screening system. The ID card for
Gram-negative bacilli for the VITEK 2 system is a 64-well plastic
card containing 41 ﬂuorescent biochemical tests, including
18 enzymatic tests for aminopeptidases and oxidases. The VITEK
2 GN cards were set up as per the manufacturer’s instructions using
reagents and equipment supplied by bioMe´rieux. Brieﬂy, individ-
ual colonies from a 24-h subculture on MacConkey agar were
selected and transferred to a polystyrene test tube containing3.0 ml of sterile saline (aqueous, 0.45% to 0.05% NaCl, pH 4.5 to 7.0).
Tubes were mixed to produce a homogeneous organism suspen-
sion and the density was adjusted to be equivalent to a McFarland
number of 0.50 to 0.63 using a calibrated VITEK 2 Densichek. All
inoculated cards were placed in the instrument within 30 min of
inoculation. Data were analyzed using software version VT2 4.01–
7.01.
Four quality control strains (Escherichia coli ATCC 25922,
Klebsiella pneumoniae ATCC 700603, Pseudomonas aeruginosa ATCC
27853, E. coli ATCC 32218, Enterobacter hormaechei ATCC 700323,
Stenotrophomonas maltophilia ATCC 17666) were loaded with each
study batch. All quality control strains had to be identiﬁed
correctly in order to allow ID of the test strains. In this study, the
system produced a result listed as ‘very good’ (93% to 95%
probability) or ‘excellent’ (96% to 99% probability) for the
identiﬁcation of B. pseudomallei.
The main features of identiﬁcation were the following: Gram-
negative rods with bipolar staining, oxidase-positive; rough,
wrinkled, and pink colonies on MacConkey agar; oxidative
utilization of glucose, lactose, and maltose; lysine decarboxyl-
ase-negative; arginine dihydrolase-positive; reduction of nitrates;
resistance to gentamicin and polymyxin B and susceptibility to
ceftazidime, trimethoprim–sulfamethoxazole, carbapenems, tet-
racycline, and amoxicillin–clavulanic acid.
Other diagnostic methods, such as the latex agglutination test
and molecular biology tests, are not available in Colombia.
In the series presented, ﬁve patients had a bacteremic form with
shock and pulmonary compromise and two of them died. Two
patients had non-bacteremic melioidosis with genitourinary,
abdominal, and osteoarticular compromise. All patients had
comorbidities and lived in rural hot and humid areas in the west
central region of Colombia (Antioquia). Diabetes mellitus, chronic
renal failure (CRF), chronic obstructive pulmonary disease (COPD),
and other chronic diseases are important risk factors for the
development of severe forms of melioidosis.
2.1. Patient 1
Patient 1 was a 10-year-old female school student, living in the
rural Puerto Berrı´o, a hot and humid area. She had been
deteriorating progressively over a 4-month period and had
symmetric arthritis in the elbows, knees, and ankles as a result
of connective tissue disease (CTD). A week before her admission to
HUSVP, she presented jaundice, fever, abdominal pain, hematem-
esis, and exanthema. On admission, she was pale and jaundiced,
with hypotension, tachycardia, and tachypnea. Since disseminat-
ed vesicles and petechiae were seen, meningococcemia was
diagnosed, and she was transferred to the intensive care unit
(ICU). She presented progressive impairment with respiratory
failure, severe hypoxemia (arterial oxygen saturation (SaO2) of
54%), hemoptysis, and multiorgan dysfunction, and required
mechanical ventilation and cardiovascular support. Chest X-rays
showed multilobar pneumonia. She died 12 h after her admission.
A postmortem diagnosis was established by means of blood
cultures.
2.2. Patient 2
Patient 2 was 40-year-old male farmer, living in rural
Can˜asgordas, a hot and humid area; he had a history of diabetes
mellitus. The patient complained of dyspnea and initially attended
the local hospital where he received treatment for the presumed
diagnosis of asthmatic crisis. He was then transferred to HUSVP
due to a lack of response.
On admission, the patient was jaundiced, febrile, had tachycar-
dia, and was experiencing respiratory difﬁculty, with bilateral
Table 1
Clinical and epidemiological characteristics
Features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Sex Female Male Female Male Male Male Male
Age, years 10 40 46 52 65 60 31
Area of origin Rural Rural Rural Urban Rural Rural Urban
Date attended May 2003 July 2003 October 2004 April 2005 August 1998 August 1998 November 2012
Occupation Student Farmer House wife Driver Farmer Farmer Prisoner
Previous disease CTD DM CRF DM, HTA, UI COPD DM HIV
Duration of symptoms 4 months 2 days 2 months 3 months 4 months 1 month 8 months
Month and year of diagnosis May 2003 July 2003 October 2004 April 2005 April 2005 April 1998 November 2012
Season Winter and rainfall
season
Summer season with
rainfall
Winter and rainfall
season
Winter and rainfall
season
Winter and rainfall
season
Winter and rainfall
season
Winter and rainfall
season
Main symptoms
Fever >38 8C + +  + + + +
Cough + + +   + +
Hemoptysis + +     
Dyspnea + + +    +
Vomiting +    +  
Jaundice + +     
Epistaxis + +     
SST +     + +
Type of compromise and
organs and systems
affected
Cons Sx
Syst Sx
Pulmonary
GUT
SST
HC
Liver
Syst Sx
CV
GUT
OA
Liver
Cons Sx
Syst Sx
Pulmonary
CV
Liver
Neurological
OA
Renal
Syst Sx
OA
Neurological
ASV
Cons Sx
Syst Sx
GUT
HC
Liver
Spleen Prostate
GIT
Cons Sx
Syst Sx
Pulmonary
SST
OA
Spleen
Cons Sx
Syst Sx
Pulmonary
GUT
GIT
SST
Liver
Spleen
Physical examination
Heart rate/min 130 136 100 110 88 100 107
Breathing rate/min 45 32 42 20 16 18 26
Blood pressure, mmHg 99/44 110/70 130/50 140/65 130/70 120/80 128/73
ICU and MV requirement yes yes yes No No No No
Hospital outcome Died Died Survived Survived Survived Survived Survived
Australian classiﬁcation Bacteremic with shock
and pulmonary
compromise
Bacteremic with shock
and pulmonary
compromise
Bacteremic with
shock and pulmonary,
renal, and OA compromise
Non-bacteremic with GUT
and OA compromise
Non-bacteremic
with GUT and splenic
compromise
Bacteremic with
pulmonary, renal,
and splenic compromise
Bacteremic with
pulmonary, renal, and
splenic compromise
Howe classiﬁcation Acute, sudden, with shock Acute, sudden, with shock Acute with pneumonia Chronic Chronic Acute with pneumonia Chronic
ASV, abscesses seminal vesicles; Cons Sx, constitutional symptoms (fatigue, weakness and weight loss); COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CTD, connective tissue disease; CV, cardiovascular
(tachycardia, hypertension and shock); DM, diabetesmellitus; GIT, gastrointestinal tract; GUT, genitourinary tract; HC, hematological compromise; HIV, human immunodeﬁciency virus; HTA, arterial hypertension; MV,mechanical
ventilation ; OA, osteoarticular; SST, skin and soft tissue; Syst Sx, systemic symptoms (fever and chills); ICU, intensive care unit; UI, urinary infection.
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Table 2
Laboratory results
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Glucose, mg/dl 82.0 611.0 108 132 106 253 117
Potassium, mg/dl 2.6 3.10 5.6 3.5 4.9 4.8 4.39
Sodium, mg/dl 136.0 147 143 142 128 145 133
Blood urea nitrogen 41.0 118.0 NA NA 14 12.3 17.17
Creatinine, mg/dl 0.10 7.2 15.4 1.7 1.19 1.09 1.7
Total bilirubin, mg/dl 3.90 3.7 NA 0.32 0.17 0.84 NA
Direct bilirubin, mg/dl 2.50 2.8 NA 0.06 0.06 0.47 NA
AST, U/l 721 274 NA 48 26.4 81 NA
ALT, U/l 130 117 NA 44 40 75 NA
Hb, g% 4.6 11.5 7.7 11.4 9.6 9.5 8.5
Hematocrit 13.5 33.9 23.2 33.3 30 31 NA
WBC 109/l 24 4.8 11.6 13.3 11.7 12.6 11.28
Neutrophils, % 87.8 90.0 80.0 83.5 74 83 85.9
Platelets, 109/l 6 18 91 168 410 158 228
Prothrombin time, s NDC 10.2 11.8 11.3 13 12.3 10.5
SaO2 54% NA 70% NA NA NA 99%
Culture sample Blood Blood Blood Urine Urine Blood
Pleura
Urine
Blood
Hospital outcome Decease Decease Alive Alive Alive Alive Alive
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; NA, data not available; NDC, no detection of coagulum; SaO2, arterial oxygen saturation;
WBC, white blood cell count.
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treatment was started with supportive measures and intravenous
crystalline penicillin. Because of hemodynamic compromise and
respiratory failure, he was transferred to the ICU where mechanical
ventilation and cardiovascular support were initiated. Chest X-rays
showed mixed inﬁltrates in both pulmonary ﬁelds, with large
compromise of the upper right lobe. The patient died. A
postmortem diagnosis was established by blood cultures.
2.3. Patient 3
Patient 3 was a previously healthy 46-year-old female
housewife, living in the rural area of Zaragoza, also a hot and
humid area. She presented a 2-month evolution of general malaise,
weight loss, asthenia, fever, non-productive cough, and back pain.
She received symptomatic treatment at the local hospital and then
later returned due to alterations in consciousness. She was then
transferred to HUSVP. On admission she presented alterations in
consciousness, mucocutaneous paleness, hypoperfusion, hypoten-
sion, tachycardia, respiratory failure with scattered ronchi, and
SaO2 of 70%. Laboratory tests showed anemia and kidney failure. A
diagnosis of acute renal failure, acute respiratory failure, and sepsis
was made and she was transferred to the ICU. Mechanical
ventilation and cardiovascular support were given and hemodial-
ysis was performed. She was started on meropenem. A chest X-ray
showed a bilateral alveolar inﬁltrate mostly in the right lung ﬁeld.
She recovered, but 10 days later the fever reappeared; blood
cultures had yielded B. pseudomallei and so meropenem was
reinstated for 2 weeks and then oral trimethoprim–sulfamethox-
azole was given to complete 20 weeks. The patient was followed up
and made a complete recovery.
2.4. Patient 4
Patient 4 was a 52-year-old male driver, living in the urban area
of Puerto Berrı´o, who had a history of hypertension, diabetes
mellitus, and recurrent urinary tract infection. He was seen at
HUSVP because of fever, general uneasiness, chills, myalgia,
arthralgia in the right foot and ankles, and fetid urine during
the last 3 days. Six hours later, he experienced repeated episodes of
anxiety, dizziness, syncope, and alterations in consciousness and
was transferred to the ICU. Laboratory ﬁndings showed pyuria and
hematuria, and urine culture grew 5000 CFU/ml of Gram-negativebacilli. An abdominal CT showed pyelonephritis and lesions in the
seminal vesicle. The patient received empiric therapy with
ceftriaxone and doxycycline. He developed arthritis and tenosyn-
ovitis in the right ankle. Magnetic resonance imaging demonstrat-
ed osteomyelitis and tibiotalar arthritis. A new urine culture
yielded B. pseudomallei.
The diagnosis was non-bacteremic melioidosis, with urinary
and osteoarticular compromise. He received treatment with
intravenous ceftazidime and oral trimethoprim–sulfamethoxazole
for 2 weeks, with a satisfactory clinical evolution, and made a
complete recovery. Oral trimethoprim–sulfamethoxazole was
administered to complete 20 weeks.
2.5. Patient 5
Patient 5 was a 65-year-old male farmer, living in the rural area
of Liborina, who had a history of smoking and COPD. He was seen at
HPTU because of 4 months of fever, general uneasiness, chills,
myalgia, nausea and vomiting, and weight loss of 20 kg, and in the
most recent 2 weeks he had produced fetid urine and had dysuria
and oliguria. Fever, tachycardia, pallor, and abdominal pain were
documented on hospital admission. Laboratory ﬁndings showed
pyuria, hematuria, and bacteria in the urinary sediment. A chest X-
ray was normal and an abdominal CT scan showed splenic and
prostatic abscesses. Transrectal prostate ultrasonography con-
ﬁrmed multiple abscesses. The patient received empiric treatment
with norﬂoxacin. Urine culture yielded B. pseudomallei and blood
cultures were negative. The patient underwent a splenectomy. The
diagnosis was non-bacteremic melioidosis, with urinary and
splenic compromise. He received treatment with endovenous
ceftazidime and oral trimethoprim–sulfamethoxazole for 4 weeks
and then oral doxycycline plus trimethoprim–sulfamethoxazole
for 3 months. The patient had a satisfactory clinical evolution and
made a complete recovery.
2.6. Patient 6
Patient 6 was a 60-year-old male farmer, living in the rural area
of San Jero´nimo, which is hot and dry–humid. He had been
diagnosed with diabetes 10 years previously. He presented with a
1-month evolution of general uneasiness, weight loss, asthenia,
fever, and a non-productive cough. During the last week, he had
experienced chest pain, skin lesions, soft tissue rib cage pain, and
Figure 1. Radiographic and computed tomography (CT) characteristics. (1) Female patient with extended bilateral consolidation (aerial bronchogram; acute respiratory
distress syndrome). (2) Male patient with mixed inﬁltrates in both ﬁelds, with a well-deﬁned area of consolidation in the upper right lobe. (3) Female patient with bilateral
inﬁltrates of alveolar occupation in the lower lobes and with larger extension in the right lobe. (4) Male patient with compromise of the urinary tract. The CT shows
pyelonephritis and lesions in the seminal vesicles; prostate lesions were not documented. (7) Male patient: X-ray of the thorax shows a diffuse interstitial inﬁltrate and the
thoraco-abdominal CT scan shows necrotizing pneumonia and multiple intra-abdominal collections, such as splenic and hepatic abscesses.
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mucocutaneous paleness, tachycardia, skin lesions and soft tissue
rib cage lesions, and basal pulmonary rales. Laboratory tests
showed anemia and hyperglycemia. A chest X-ray showed a
bilateral alveolar inﬁltrate mostly on the right lung ﬁeld plus
pleural effusion. An abdominal CT scan showed multiple splenic
abscesses. The patient received empirical treatment with oxacillin,
gentamicin, and ciproﬂoxacin. After studying the pleural ﬂuid, a
diagnosis of empyema was made. The patient presented
hemothorax post puncture and required a thoracotomy. The
patient underwent splenectomy for splenic abscess. Pleural ﬂuid
cultures and blood cultures were positive for B. pseudomallei. The
diagnosis of bacteremic melioidosis was made. Intravenous
imipenem and trimethoprim–sulfamethoxazole were started for4 weeks, followed by oral trimethoprim–sulfamethoxazole,
doxycycline, and chloramphenicol in order to complete 3 months.
At the follow-up, the patient had recovered completely.
2.7. Patient 7
Patient 7 was a 31-year-old male prisoner in Bella-Vista Jail,
Bello-Antioquia, which has a temperature determined by thermal
ﬂoors; however, he had been in Puerto Berrı´o 1 year ago. He had
been diagnosed with HIV 27 months previously. He presented an
8-month clinical evolution of self-limited episodes of diarrhea,
without mucus or abdominal pain; he also presented violet lesions
on the skin. Two months previously, the symptoms had been
accompanied by general uneasiness, non-quantiﬁed weight loss,
Figure 2. Geographic location of the cases. Colombia is located in the northwest of South America, between 1282604600 north latitude (Punta Gallinas – Guajira Peninsula) and
481203000 south latitude (Amazon River), over the equinoctial line in the Torrid Zone. Colombia is bordered by the Caribbean Sea to the north and the Paciﬁc Ocean to the west.
It borders Panama to the northwest, Venezuela and Brazil to the east, and Ecuador and Peru to the south. As a tropical country, Colombia has only two seasons: winter and
summer. Intense rainfall can occur in both of these seasons. The Department of Antioquia is situated in Colombia between 885502200 north latitude (Punta Arboletes) and the
582503000 south latitude (Cerro Caramanta). The climate of Antioquia is diverse, and is hot at sea level in Uraba´ up to the moor at a maximum altitude of 4080 m above sea level
in Pa´ramo de Sabana or Frontino. Antioquia has extended wild and mountainous zones.
F.E. Montu´far et al. / International Journal of Infectious Diseases 37 (2015) 50–57 55asthenia, episodes of fever, nocturnal diaphoresis, dyspnea, and an
intensiﬁed productive cough. On admission to the Leon XIII Clinic
of Antioquia University, a chest X-ray showed a diffuse interstitial
inﬁltrate and consolidation compatible with pneumonia. The
patient received therapy with piperacillin–tazobactam, trimetho-
prim–sulfamethoxazole, and clarithromycin. An incidental ﬁnding
revealed a urine culture positive for B. pseudomallei, therefore it
was decided to change the therapy to ceftazidime. Two blood
cultures were positive for B. pseudomallei. A thoraco-abdominal CT
scan showed necrotizing pneumonia and multiple intra-abdomi-
nal collections, such as splenic and hepatic abscesses, all of them
caused by the same microorganism. Ceftazidime was prescribed
for 2 weeks, followed by oral trimethoprim–sulfamethoxazole plus
doxycycline, with a good outcome. In the ﬁrst approach, no
opportunistic infections were documented. Subsequently the
patient developed a febrile syndrome and new investigations for
opportunistic infections were performed. An immune reconstitu-
tion syndrome (IRIS) was established as the cause of the febrileTable 3
Ecological characteristics and geographic location
Municipality
(Case(s))
Latitude Average temperature, 8C Month a
Puerto Berrı´o
(Cases 1 and 4)
682902600N 29 May 20
April 20
Zaragoza
(Case 2)
782902300N 36 July 200
Can˜asgordas
(Case 3)
684405900N 21 October
San Jero´nimo
(Cases 5 and 6)
682603000N 25 April 20
April 19
Bello
(Case 7)
681905500N 26.7 Novemb
a As a tropical country, Colombia has only two seasons: winter and summer. Intense ra
tropical convergence point and is inﬂuenced by the winds from the northern and southern
vapors and moisture from the two oceans to concentrate, forming cloud masses that k
b Meters above sea level.episode. Prednisolone and trimethoprim–sulfamethoxazole plus
doxycycline were initiated and the patient was discharged to
home. Fifteen days later the patient returned to the hospital
because of herpes-like perianal ulcers, which were treated with
aciclovir. The patient was tested again for tuberculosis and this
infection was documented by a positive bronchoalveolar lavage for
Mycobacterium spp. The patient was sent home with a tuberculosis
scheme plus treatment for melioidosis. The patient made
satisfactory clinical progress.
3. Discussion
Few cases of melioidosis have been reported in Latin America.12
Two cases presenting in the USA were thought to have been
acquired in Honduras.18,32 Two cases have also been reported from
Puerto Rico: severe melioidosis in a patient with chronic
granulomatous disease and a case of the disorder described in a
patient with diabetes.18 Some cases have been reported fromnd year of diagnosis Seasona Altitude,b m
03
05
Winter and rainfall season 125
3 Summer season with rainfall 50
 2004 Winter and rainfall season 1320
05
98
Winter and rainfall season 750
er 2012 Winter and rainfall season 1250
infall can occur in both seasons. By location, Colombia is at the equatorial and inter-
 Caribbean, the Paciﬁc, and the great Amazon plain. The altitude of Antioquia allows
eep the average annual rainfall at around 2500 mm.37
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many cases in the Americas per se, there has been an increase in
the number of cases in Brazil. Brilhante et al. described 13 cases of
melioidosis in Ceara´, Brazil.33 Only one case has been reported in
Argentina.34 A few cases have been reported in Colombia, including
two cases of non-bacteremic melioidosis.12–14
B. pseudomallei has become the most frequent etiology of CAP in
endemic regions such as northern Australia. Likewise pneumonia
with or without bacteremia is the most common clinical
presentation of the disease and represents more than half of the
cases.8,15,35 Bacteremic spread can result in clinical manifestations
involving virtually any site. Overall, around half of patients are
bacteremic and up to a quarter can present with septic shock.11 The
remaining patients present non-bacteremic clinical forms. Pneu-
monia is the most common clinical presentation of melioidosis in
all studies.11,15,35,36 Bone and joint infections are uncommon and
may be difﬁcult to differentiate from other causes of infection;
surgical drainage is often required, together with long courses of
intravenous antibiotics.8,15,25,35 In the Darwin Prospective Study,
540 cases of culture-conﬁrmed melioidosis were followed
prospectively in northern Australia over 20 years; 28% of patients
without bacteremia presented with skin ulcers or abscesses.10
Genitourinary melioidosis presents with fever in association with
suprapubic pain, dysuria, difﬁculty passing urine, or acute urinary
retention requiring catheterization. A tender, boggy prostate may
be found on rectal examination. Abscesses in the internal organs
are well recognized, especially in the spleen, kidney, prostate, and
liver. Fevers, chills, and rigors with and without hypotension are
common, but localizing symptoms are often absent.5
In this report, the cases of seven patients with melioidosis are
described; ﬁve were men, the average age of all patients was
43.4 years and ﬁve of them lived in rural areas of Antioquia. These
patients presented different comorbidities: diabetes mellitus (n =
3), COPD (n = 1), CRF (n = 1), CTD (n = 1), and HIV (n = 1). Five
patients had bacteremic melioidosis, three of whom had the
bacteremic form with shock and pulmonary compromise; two
patients had the non-bacteremic form with genitourinary,
abdominal, and osteoarticular compromise. Two patients died.
The sociodemographic and epidemiological features were similar
to those of cases reported in Brazil, where this pathology has been
considered an emerging disease since 2003, with 13 cases reported
up to 2011.33
All of the patients in the present series had co-morbidities.
Diabetes mellitus, CRF, COPD, HIV, and other chronic diseases are
important risk factors for the development of severe forms of
melioidosis, as was identiﬁed in this study. All of the case patients
lived in rural hot and humid areas in the west central region of
Colombia (Antioquia). In six cases, the disease occurred in the
winter season in conditions of intense rainfall; one case occurred
during the summer season but during a period of rainfall.37
There are some reported risk factors for melioidosis. Between
37% and 60% of patients with the disease have been found to be
diabetic, mainly type 2. All series reported from Australia,
Thailand, Malaysia, and Singapore have demonstrated a male
preponderance. It has been established that renal impairment
or renal failure is also associated with an increased risk of
melioidosis.4
The present series showed the occurrence of the bacteremic
form of melioidosis with pulmonary, urinary, and splenic
involvement in a patient with an HIV infection. This situation
has not been described previously, and highlights the fact that
this type of immunosuppression can also promote the presentation
of widespread and severe forms.
Melioidosis in Antioquia, Colombia is similar to descriptions
of the disease from endemic areas regarding comorbidities, risk
factors, clinical presentation, and environmental conditions.The detection of these cases in areas where the disease is
possible indicates the need to establish whether melioidosis is an
endemic and under-diagnosed disease or an emerging disease in
Colombia. A prospective study is required, with the implementa-
tion of other diagnostic methods such as serological tests, the latex
agglutination test, or molecular biology tests in our institutions, to
determine their true prevalence and incidence of this disease.
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